PBYI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PBYI is not a good buy right now. Despite a mildly constructive moving-average setup and a small pre-market uptick (~$6.50), the momentum read is weakening (MACD histogram negative and expanding), expected near-term edge is poor (pattern-based: -4.89% over next month), and both hedge funds and insiders are actively selling (hedge selling +203% QoQ; insider selling +231% MoM). For an impatient buyer looking for immediate follow-through, the risk/reward is unfavorable at current levels near resistance overhead.
Trend/structure: Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader trend has been improving. Momentum: MACD histogram is below zero (-0.0326) and negatively expanding, signaling fading upside momentum and increasing downside pressure. RSI(6) ~49.4 is neutral—no oversold bounce signal. Key levels: Pivot 6.666; support S1 6.303 then S2 6.079; resistance R1 7.029 then R2 7.253. With pre-market around 6.5, price sits below the pivot and closer to support than resistance, meaning a break below ~6.30 could accelerate weakness, while upside likely needs a reclaim of ~6.67 to target ~7.03.
Intellectia Proprietary Trading Signals
Technical backdrop from moving averages remains constructive (SMA_5 > SMA_20 > SMA_200), leaving room for a push toward ~7.03 if price reclaims the ~6.67 pivot.
Gross margin improved sharply in 2025/Q3 (77.65%, +21.58% YoY), indicating better profitability per dollar of revenue.
Clear distribution signals: hedge funds selling (+203.10% QoQ) and insiders selling (+230.93% MoM).
Momentum deterioration: MACD histogram negative and worsening.
Growth is contracting: 2025/Q3 revenue -32.36% YoY, net income -56.47% YoY, EPS -58.54% YoY.
News flow provided is macro/Europe-India trade related and not a direct, stock-specific catalyst for PBYI.
Pattern-based outlook is weak over a month (-4.89% expected move).
Latest reported quarter: 2025/Q3. Revenue fell to $54.48M (-32.36% YoY). Net income fell to $8.84M (-56.47% YoY) and EPS dropped to $0.17 (-58.54% YoY). The main positive was gross margin expansion to 77.65% (+21.58% YoY), but the overall picture is shrinking top-line and sharply lower earnings—consistent with a challenged growth trend.
No analyst rating or price target change data was provided, so a clear Wall Street consensus trend cannot be confirmed here. Based on the available fundamentals and flow (insider/hedge selling + earnings declines), the balance of pros/cons leans negative: Pros—improved gross margin and a still-constructive MA stack; Cons—steep YoY declines in revenue/earnings and strong selling pressure from informed holders. Politicians/congress: no recent congress trading data available and no notable influential-figure transactions were provided.
